Resection of primary lesion for patients with metastatic breast cancer: where are we now?

被引:6
|
作者
Hu, Qiancheng [1 ]
Zhong, Xiaorong [1 ,2 ,3 ]
Liu, Xu [2 ]
Xie, Yuxin [1 ,2 ]
Hu, Kejia [2 ]
He, Ping [1 ,3 ]
Lu, Donghao [1 ,3 ,4 ]
Zheng, Hong [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Med Sch, West China Hosp, Dept Med Oncol,Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Med Sch, West China Hosp,Natl Collaborat Innovat Ctr Bioth, State Key Lab Biotherapy,Lab Tumor Mol Diag, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Chengdu 610041, Sichuan, Peoples R China
[4] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
基金
中国国家自然科学基金;
关键词
Breast cancer; distant metastasis; resection of the primary lesion;
D O I
10.21037/cco.2018.05.03
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is largely unclear that whether or not surgical resection of the primary tumors could confer survival benefit among patients with metastatic breast cancer at initial presentation. We thoroughly reviewed the up-to-date evidence on surgical resection of the primary lesion in metastatic breast cancer, including comparative studies (of particular interest in risk modifiers, the type, and timing of surgical procedures), Chinese and international guidelines, as well as the progress of clinical trials. Partial modified radical mastectomy and breast-conserving surgery are by far the most common choices for patients with metastatic breast cancer. Patients with certain characteristics, for example, younger than 45 years of age or with oligometastasis, might benefit from the surgery. The type and timing of surgical procedures are still in debate according to the guidelines from different countries. Forthcoming evidence from the ongoing clinical trials might help close the knowledge gaps in surgical treatment for patients with metastatic breast cancer and aid the decision-making in clinical practice.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Primary tumor resection improves the survival of younger patients with metastatic breast cancer
    Shien, Tadahiko
    Kinoshita, Takayuki
    Shimizu, Chikako
    Hojo, Takashi
    Taira, Naruto
    Doihara, Hiroyoshi
    Akashi-Tanaka, Sadako
    ONCOLOGY REPORTS, 2009, 21 (03) : 827 - 832
  • [22] Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?
    Holler, Anna
    Nguyen-Strauli, Bich Doan
    Frauchiger-Heuer, Heike
    Ring, Alexander
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 525 - 540
  • [23] High-dose chemotherapy in breast cancer: Where are we now?
    Dicato, M
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 16 - 20
  • [24] New biomarkers in breast cancer: microRNAs and leptins - where are we now?
    Keith, Tamara
    Amber, Vian
    Stebbing, Justin
    BIOMARKERS IN MEDICINE, 2007, 1 (01) : 9 - 11
  • [25] Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
    Teng, Yvonne H. -F.
    Thike, Aye-Aye
    Wong, Nan-Soon
    Tan, Puay-Hoon
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2011, 6 (02) : 196 - 209
  • [26] BM micrometastases and circulating tumor cells in breast cancer patients:: where have we been, where are we now and where does the future lie?
    Müller, V
    Pantel, K
    CYTOTHERAPY, 2005, 7 (06) : 478 - 482
  • [27] Significance of primary lesion resection in Stage IV breast cancer
    Shien, Tadahiko
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 381 - 384
  • [28] Cancer Vaccines - where are we now?
    Mkele, Gail
    SA PHARMACEUTICAL JOURNAL, 2010, 77 (07) : 37 - +
  • [29] CANCER OF THE PROSTATE - WHERE ARE WE NOW
    BLANDY, J
    PRACTITIONER, 1989, 233 (1468) : 636 - &
  • [30] Cancer anorexia - Where are we now?
    不详
    EUROPEAN JOURNAL OF CANCER CARE, 2004, 13 (01) : 4 - 5